First person dosed in US study for potential coronavirus vaccine, officials say
The first-ever clinical trial in a quest for a coronavirus vaccine began Monday as the first injections were administered at Kaiser Permanente Washington Health Research Institute in Seattle.
The first-ever clinical trial in a quest for a coronavirus vaccine began Monday as the first injections were administered at Kaiser Permanente Washington Health Research Institute in Seattle.
Four volunteer participants were given injections of a vaccine created by Moderna Inc. in collaboration with the Vaccine Research Center (VRC) and the National Institute of Allergy and Infectious Diseases (NIAID). Phase 1 of the study is intended to test the safety of three dose levels of the new vaccine -- mRNA-1273 -- named after the genetic material that makes up the injections and which researchers say can produce a vaccine very quickly.
"This study is the first step in the clinical development of an mRNA vaccine" against coronavirus, said Dr. Tal Zaks, chief medical officer at Moderna, in a statement.
The trial will include 45 healthy adults ages 18 to 55. Each participant will receive two shots, 28 days apart. Three different doses will be tested on 15 people each and the participants will be studied to determine whether the vaccine is safe. Click here for more.
Other related developments:
- First coronavirus death recorded in Texas: reports
- Coronavirus: Everything you need to know
- Dollar General stores, others set specific hours for older shoppers for their protection.
- First coronavirus death recorded in Texas: reports
- Coronavirus: Everything you need to know
- Dollar General stores, others set specific hours for older shoppers for their protection.
No hay comentarios:
Publicar un comentario